On July 3, MicroPort MedBot-B rose 5.84% in regular trading, trading at HK$25.62/share, with turnover of HK$87.19 million. The rally was driven by continued market enthusiasm over the Toumai laparoscopic surgical robot's multiple commercialization milestones, compounded by broad strength across Hong Kong-listed robotics concept stocks.

On the news front, the company recently announced that Toumai's global commercial installations surpassed 200 units, with the 200th deployed at Spain's HM Hospitales. All installations have received end-customer acceptance reports. Global commercial orders have exceeded 300 units, with total orders approaching 400. Notably, new orders in the first half already surpassed the full-year total of the prior year. In June, Toumai's remote surgery full-department application received EU CE certification, making it the world's first remote surgical robot to obtain this approval, with regulatory clearance in nearly 20 countries and regions.

CITIC Construction Investment maintains a Buy rating on the company, citing strong overseas volume growth and expecting total revenue to double year-over-year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)